Suppr超能文献

从 T 细胞衍生的诱导多能干细胞生成 TCR 阴性 CD8αβ+ CAR T 细胞。

Generation of T-cell-receptor-negative CD8αβ-positive CAR T cells from T-cell-derived induced pluripotent stem cells.

机构信息

Center for Cell Engineering, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

Immunology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

出版信息

Nat Biomed Eng. 2022 Nov;6(11):1284-1297. doi: 10.1038/s41551-022-00915-0. Epub 2022 Aug 8.

Abstract

The production of autologous T cells expressing a chimaeric antigen receptor (CAR) is time-consuming, costly and occasionally unsuccessful. T-cell-derived induced pluripotent stem cells (TiPS) are a promising source for the generation of 'off-the-shelf' CAR T cells, but the in vitro differentiation of TiPS often yields T cells with suboptimal features. Here we show that the premature expression of the T-cell receptor (TCR) or a constitutively expressed CAR in TiPS promotes the acquisition of an innate phenotype, which can be averted by disabling the TCR and relying on the CAR to drive differentiation. Delaying CAR expression and calibrating its signalling strength in TiPS enabled the generation of human TCR CD8αβ CAR T cells that perform similarly to CD8αβ CAR T cells from peripheral blood, achieving effective tumour control on systemic administration in a mouse model of leukaemia and without causing graft-versus-host disease. Driving T-cell maturation in TiPS in the absence of a TCR by taking advantage of a CAR may facilitate the large-scale development of potent allogeneic CD8αβ T cells for a broad range of immunotherapies.

摘要

自体 T 细胞表达嵌合抗原受体(CAR)的生产既耗时、昂贵,有时又不成功。T 细胞衍生的诱导多能干细胞(TiPS)是生成“现成”CAR T 细胞的有前途的来源,但 TiPS 的体外分化通常会产生特征不理想的 T 细胞。在这里,我们表明 TiPS 中过早表达 T 细胞受体(TCR)或组成型表达的 CAR 会促进获得先天表型,而通过禁用 TCR 并依赖 CAR 来驱动分化可以避免这种情况。延迟 CAR 表达并校准其在 TiPS 中的信号强度,可生成与外周血中的 CD8αβ CAR T 细胞性能相似的人类 TCR CD8αβ CAR T 细胞,在白血病的小鼠模型中通过系统给药实现有效的肿瘤控制,而不会引起移植物抗宿主病。通过利用 CAR 在没有 TCR 的情况下驱动 T 细胞成熟,可能有助于大规模开发用于广泛免疫疗法的强效同种异体 CD8αβ T 细胞。

相似文献

引用本文的文献

7
"Attack!" Cellular Therapies to Attack Pathogens and Tumors.“攻击!”用于攻击病原体和肿瘤的细胞疗法。
Transfus Med Hemother. 2025 Feb 4;52(1):1-4. doi: 10.1159/000543415. eCollection 2025 Feb.

本文引用的文献

4
CAR T cells: Building on the CD19 paradigm.嵌合抗原受体 T 细胞:以 CD19 为范例。
Eur J Immunol. 2021 Sep;51(9):2151-2163. doi: 10.1002/eji.202049064. Epub 2021 Aug 2.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验